Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Equine Thymocyte Immune Globulin · Atgam

Plasma-derived product · Immune activation, directed at T-lymphocytes · developed by Pharmacia & Upjohn Company LLC

Approved FDA, Dec 1996

1 Registered trials

What is Equine Thymocyte Immune Globulin?

Equine thymocyte immune globulin (hATG) is a purified horse-derived gamma globulin that recognizes and depletes T-lymphocytes. It reduces T-cell activation and modulates cytotoxic activities, providing immunosuppression. It is studied in aplastic anemia and hypoplastic myelodysplastic syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Atgam, horse anti-thymocyte globulin (hATG)
Drug type: Plasma-derived product
Targets: T-lymphocytes
Mechanism: Immune activation, directed at T-lymphocytes
Pathways: T-cell depletion, T-cell activation reduction, cytotoxic activity modulation
Therapy area: Hematology
Developer: Pharmacia & Upjohn Company LLC
In trials of: BLRX
FDA status: Approved as Atgam (December 4, 1996), BLA103676
UNII: 475247QF1Z

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT02462252	Phase 2	Aplastic Anemia	Completed	BLRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Aplastic AnemiaHypoplastic Myelodysplastic Syndrome

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z